Precision Biosciences opened lower at $8.97, compared with its previous close of $9.15. In the last trading session, the stock traded between $7.97 and $9.00. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Precision Biosciences is now worth
$ 2.61
Resulting in a loss of
$ 97.39 (97.39%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-1.12 (-12.24%)
Day High
$9.00
Day Low
$7.97
Day Open
$8.97
Prev Close
$9.15
Volume
3,77,408
1W Return
-1.06%
1M Return
22.78%
3M Return
6.81%
6M Return
2.16%
1Y Return
33.83%
Market Cap ($ Mn)
224
PE Ratio
-
PB Ratio
4.54
PEG Ratio
-
ROE
-93.72%
ROCE
-44.70%
EPS (TTM)
$-0.27
1 Week
-1.06%
1 Month
22.78%
3 Months
6.81%
6 Months
2.16%
9 Months
97.30%
Precision BioSciences Q3 Results: Adjusted loss narrows to $0.74 per share
Adjusted loss per share was $(0.74), beating the $(0.85) estimate by 12.94%. Losses narrowed 59.78% YoY from $(1.84) in the prior year quarter. Result reflects improved financial performance relative to market expectations.
9 days agoPrecision BioSciences doses first patient in Phase 1/2 DMD trial
Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD trial in August. PBGENE-DMD targets mutations in exons 45-55, affecting up to 60% of boys with DMD. Initial safety data from the trial is expected by year-end 2026. The therapy uses ARCUS nucleases to excise defective gene portions and restore dystrophin.
2mo agoHC Wainwright Reiterates Buy on Precision BioSciences, Holds $60 Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterated a Buy rating on Precision BioSciences (NASDAQ: DTIL). The firm maintained its $60 price target, indicating no change in its valuation outlook for the biotechnology company.
3mo agoPrecision BioSciences promotes Kelly to COO, Tanna to CFO
Precision BioSciences Inc. (NASDAQ: DTIL) announces internal promotions of Alex Kelly to Chief Operating Officer and Naresh Tanna to Chief Financial Officer, effective August 1, 2026. The leadership changes aim to support the clinical development of its lead gene editing therapies for chronic hepatitis B and Duchenne muscular dystrophy.
3mo agoPrecision BioSciences grants 114,622 RSUs to new hires
Precision BioSciences granted 114,622 RSUs to three new employees on July 5, 2026, under its 2021 Employment Inducement Incentive Award Plan. The awards, approved by the Compensation Committee, vest annually over three years. The company focuses on in vivo gene editing therapies using its ARCUS platform.
4mo agoHC Wainwright reiterates Buy on Precision BioSciences, maintains $60 target
HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a Buy rating for Precision BioSciences (NASDAQ: DTIL) with a maintained price target of $60. The endorsement reflects confidence in the company's operational and financial outlook.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Precision Biosciences is now worth
$ 2.61
Resulting in a loss of
$ 97.39 (97.39%)
Note: Past profits do not guarantee future returns.
